No Data
Volume change rate ranking (9 o'clock) ~ SHIFT, Nomura Micro, etc. made the ranking.
In the volume change rate ranking, by comparing the average volume over the last five days with the volume on the day of distribution, one can understand the trends in market participants' interests, etc. ■ Top volume change rates [As of December 25, 9:32] (Comparison of the last five days average volume) Stock Code Stock Name Volume 5-Day Average Volume Volume Change Rate Stock Price Change Rate <7578> Nichiryoku 619100 107185.08 160.12% 0% <4465> Niitaka 980
NANO MRNA---Anti-aging therapy, signed a basic agreement with Yoshio Ikeda (Director of Tokyo Dermatology and Plastic Surgery).
On the 13th, NANOMRNA <4571> announced that it had signed a basic agreement regarding collaboration on new aesthetic medical treatments using mRNA with Dr. Yoshio Ikeda of Ikeda Dermatology and Plastic Surgery in Tokyo. Furthermore, this collaboration will be promoted through a subsidiary called "Nano Rejuvenation Co., Ltd." scheduled to be established in January 2025, and it will be clearly separated from the Pharmaceutical Business. Currently, several methods such as collagen injection are being considered for skin rejuvenation.
NANO mRNA --- Establishment of the subsidiary "Nano Rejuvenation" promoting aesthetic medicine.
NANO MRNA <4571> announced on the 13th the establishment of its subsidiary 'Nano Rejuvenation' focused on cosmetic medicine. The subsidiary will promote business development in the field of aesthetic medicine related to the research of skin anti-aging therapies using mRNA, which NANO MRNA has been advancing, and will clearly separate this from the Pharmaceutical Business.
Dream Arts, along with Classicom and others.
Below is the downward revision of VIS, with this period's operating profit and loss forecast at -0.214 billion yen, down from -0.144 billion yen. The approximately 0.268 billion yen gain from the sale of Nisso's subsidiary stocks is expected to be recorded as extraordinary profit. A revision of the performance forecast for Astroscale shows this period's project revenue forecast at 12 billion yen, down from 18 billion yen. A public tender offer by Shannon Innovation for Stock 3970 will be made at a price of 650 yen per share, and the listing is expected to be maintained after the public tender offer, with the remaining 25th new share rights.
NANO MRNA---The full year financial estimates have been revised, with revenue increasing by 111% compared to the initial forecast, and the loss margin is expected to shrink.
On the 14th, NANO MRNA <4571> announced its consolidated financial results for the second quarter of the fiscal year ending March 2025 (April-September 2024). Revenue decreased by 91.5% year-on-year to 0.007 billion yen, operating loss was 0.373 billion yen (compared to a loss of 0.518 billion yen), recurring loss was 0.382 billion yen (compared to a loss of 0.471 billion yen), and net loss attributable to the parent company's shareholders was 0.518 billion yen (compared to a loss of 0.477 billion yen). Regarding the mRNA pharmaceutical pipeline, RUNX1 is targeted for osteoarthritis.
Nano Mrna: Interim report
No Data